11:46 AM EST - Oncolytics Biotech Inc. : Announced recent operational highlights and financial results for the first quarter ended March 31, 2023. As of March 31, 2023, the Company reported $29.7 million in cash, cash equivalents, and marketable securities. The net loss for the first quarter of 2023 was $6.4 million, compared to a net loss of $6.8 million for the first quarter of 2022. The basic and diluted loss per share was $0.10 in the first quarter of 2023, compared to a basic and diluted loss per share of $0.12 in the first quarter of 2022. Oncolytics Biotech Inc.
shares T.ONC are trading up $0.10 at $2.08.
